Rahimzadeh Golnar, Valadan Reza, Rezai Shaghayegh, Khosravi Mohammad, Vahedi Larijani Laleh, Sheidaei Somayeh, Nemati Hevelaee Ebrahim, Movahedi Faezeh Sadat, Rezai Raha, Sadegh Rezai Mohammad
Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Department of Immunology and Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Iran J Microbiol. 2024 Jun;16(3):314-322. doi: 10.18502/ijm.v16i3.15762.
During the coronavirus pandemic, the overuse of antibiotics to reduce coinfections and mortality may be contributing to the rise of antimicrobial resistance. In this study, we aim to investigate the antibiotic resistance changes of post-COVID-19 pandemic in Northern Iran.
The current study is a cross-sectional study. Between 2022 and 2023, 2190 clinical samples were collected from patients with healthcare-associated infections (HAIs) at four hospitals in Sari, which served as corona centers after the COVID-19 pandemic. Antimicrobial sensitivity was determined using standard broth macro-dilution, and resistance genes were detected using multiplex PCR.
Based on the results co-amoxiclav had a resistance rate of 100%, while piperacillin/tazobactam showed the least resistance rate of 29.82%. In terms of GM MIC values, colistin was the most potent against multi-drug resistant isolates. The frequency of , and genes were 100%, 99.12%, 90.35%, and 69.30% respectively.
Our study revealed high multi-drug resistance rates. Piperacillin/tazobactam recommended for treating multi-drug resistant infections in Northern Iran.
在新冠疫情期间，过度使用抗生素以减少合并感染和死亡率可能导致了抗菌药物耐药性的上升。在本研究中，我们旨在调查伊朗北部新冠疫情后抗生素耐药性的变化。
本研究为横断面研究。在2022年至2023年期间，从萨里的四家医院收集了2190份医疗保健相关感染（HAIs）患者的临床样本，这些医院在新冠疫情后作为新冠治疗中心。使用标准肉汤宏稀释法测定抗菌敏感性，并使用多重PCR检测耐药基因。
根据结果，阿莫西林克拉维酸的耐药率为100%，而哌拉西林/他唑巴坦的耐药率最低，为29.82%。就GM MIC值而言，黏菌素对多重耐药菌株最有效。 、 、 和 基因的频率分别为100%、99.12%、90.35%和69.30%。
我们的研究揭示了高多重耐药率。推荐哌拉西林/他唑巴坦用于治疗伊朗北部的多重耐药感染。
